Wells Fargo Cuts PT on Globus Medical (GMED) Despite Q1 Sales and EPS Beat
Wells Fargo cut its price target on Globus Medical (GMED) to $103 from $104 while keeping an Overweight rating, citing the company’s fiscal Q1 2026 results that beat consensus on sales and EPS, according to the report. Globus Medical reported worldwide net sales of $759.9M (+27%); base business net sales were $677.2M (+13.2%).
How this was made
The 30-second read
Why it matters
Even with operational momentum (27% worldwide net sales growth; base business up 13.2%), the PT cut implies the broker adjusted valuation or forward assumptions, which can influence near-term positioning.
Market read
Traders may treat the earnings beat as supportive but expect limited upside as sell-side valuation expectations were slightly reset.
What to watch
Focus on procedural volume and share gains in core spine plus Enabling Technologies pipeline execution; these may outweigh the modest PT adjustment if guidance remains strong.
Background
The piece centers on a Wells Fargo analyst note: a modest price-target reduction for Globus Medical while acknowledging a fiscal Q1 2026 sales/EPS beat and strong organic growth.
Ticker impact
Wells Fargo cut Globus Medical’s price target to $103 from $104 despite a fiscal Q1 sales and EPS beat, keeping Overweight.
Near-term downside bias or consolidation as PT reduction can cap upside despite strong Q1 results.
The article cites a PT reduction alongside a Q1 beat; without new negative fundamentals, the likely driver is revised valuation assumptions or forward expectations.
Market effects
Robotic/orthopedic device names may see muted read-through if sell-side trims targets even after beats, highlighting valuation sensitivity.
Limited—this is a single-company analyst action rather than a broad regional catalyst.
Low—no international regulatory or supply-chain shock is described.
Counterpoint
The PT cut is small ($103 vs $104) and the company delivered record Q1 earnings with strong organic growth, which can still support upside.
Key entities
- companyGlobus Medical, Inc.
Robotic surgery/medical device company reporting fiscal Q1 2026 sales and EPS ahead of consensus; subject of Wells Fargo PT cut.
- analyst_firmWells Fargo
Broker that reduced GMED’s price target to $103 from $104 while maintaining Overweight.
